Top Markets
Coin of the day
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
Clasificación en acciones #25934
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Precio por acción
$4.80
Capitalización bursátil
$46.24M
Cambio (1 día)
-16.52%
Cambio (1 año)
103.39%
País
CA
Comercio Edesa Biotech, Inc. (EDSA)

Categoría

Ratio P/B de Edesa Biotech, Inc. (EDSA)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Edesa Biotech, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Edesa Biotech, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US